T cells sensitized with breast tumor progenitor cell vaccine have therapeutic activity against spontaneous HER2/neu tumors

Breast Cancer Research and Treatment

Volumn 134, Issue 1, 2012, Pages 61-70

  Wang, Li Xin ^a   Plautz, Gregory E ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Animal tumor model; Breast cancer; Her2 neu; Immunotherapy; T cell

Indexed keywords

BREAST TUMOR PROGENITOR CELL VACCINE; CANCER VACCINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPITOPE; IMMUNOGLOBULIN G; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ADOPTIVE IMMUNOTHERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ANTIGEN RECOGNITION; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER STEM CELL; CONTROLLED STUDY; EFFECTOR CELL; IMMUNE RESPONSE; IN VITRO STUDY; LYMPH NODE; METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE; TH1 CELL; TRANSGENIC MOUSE; TUMOR CELL DESTRUCTION;

ANIMALS; ANTIGENS, CD; ANTIGENS, NEOPLASM; CANCER VACCINES; CARCINOMA; FEMALE; IMMUNOTHERAPY, ADOPTIVE; LYMPH NODES; LYMPHOCYTE ACTIVATION; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, TRANSGENIC; NEOPLASM TRANSPLANTATION; NEOPLASTIC STEM CELLS; RECEPTOR, ERBB-2; SPHEROIDS, CELLULAR; T-LYMPHOCYTES; TUMOR CELLS, CULTURED;

EID: 84863988030     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-011-1912-5     Document Type: Article

References (44)

1. P Dalerba RW Cho MF Clarke 2007 Cancer stem cells: models and concepts Annu Rev Med 58 267 284 17002552 10.1146/annurev.med.58.062105.204854 1:CAS:528:DC%2BD2sXisV2jtr8%3D
2. CA O'Brien A Kreso CH Jamieson 2010 Cancer stem cells and self-renewal Clin Cancer Res 16 12 3113 3120 20530701 10.1158/1078-0432.CCR-09-2824
3. T Reya SJ Morrison MF Clarke IL Weissman 2001 Stem cells, cancer, and cancer stem cells Nature 414 6859 105 111 11689955 10.1038/35102167 1:CAS:528:DC%2BD3MXot1ahs7c%3D
4. D Bonnet JE Dick 1997 Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell Nat Med 3 7 730 737 9212098 10.1038/nm0797-730 1:CAS:528:DyaK2sXkt1GrtLY%3D
5. T Lapidot C Sirard J Vormoor B Murdoch T Hoang J Caceres-Cortes M Minden B Paterson MA Caligiuri JE Dick 1994 A cell initiating human acute myeloid leukaemia after transplantation into SCID mice Nature 367 6464 645 648 7509044 10.1038/367645a0 1:STN:280:DyaK2c7ltVKrsg%3D%3D
6. M Al-Hajj MS Wicha A Benito-Hernandez SJ Morrison MF Clarke 2003 Prospective identification of tumorigenic breast cancer cells Proc Natl Acad Sci USA 100 7 3983 3988 12629218 10.1073/pnas.0530291100 1:CAS:528: DC%2BD3sXivFSqtbs%3D
7. G Dontu M Al-Hajj WM Abdallah MF Clarke MS Wicha 2003 Stem cells in normal breast development and breast cancer Cell Prolif 36 Suppl 1 59 72 14521516 10.1046/j.1365-2184.36.s.1.6.x 1:CAS:528:DC%2BD3sXpsFChtr0%3D
8. M Kakarala MS Wicha 2008 Implications of the cancer stem-cell hypothesis for breast cancer prevention and therapy J Clin Oncol 26 17 2813 2820 18539959 10.1200/JCO.2008.16.3931
9. JC Liu T Deng RS Lehal J Kim E Zacksenhaus 2007 Identification of tumorsphere- and tumor-initiating cells in HER2/Neu-induced mammary tumors Cancer Res 67 18 8671 8681 17875707 10.1158/0008-5472.CAN-07-1486 1:CAS:528:DC%2BD2sXhtVCit7rE
10. BA Reynolds S Weiss 1992 Generation of neurons and astrocytes from isolated cells of the adult mammalian central nervous system Science 255 5052 1707 1710 1553558 10.1126/science.1553558 1:STN:280:DyaK383gsFemsw%3D%3D
11. BA Reynolds S Weiss 1996 Clonal and population analyses demonstrate that an EGF-responsive mammalian embryonic CNS precursor is a stem cell Dev Biol 175 1 1 13 8608856 10.1006/dbio.1996.0090 1:CAS:528:DyaK28Xitlynt7Y%3D
12. CE Brown R Starr C Martinez B Aguilar M D'Apuzzo I Todorov, et al. 2009 Recognition and killing of brain tumor stem-like initiating cells by CD8+ cytolytic T cells Cancer Res 69 23 8886 8893 19903840 10.1158/0008-5472.CAN-09- 2687 1:CAS:528:DC%2BD1MXhsV2itLvN
13. S Pellegatta PL Poliani D Corno F Menghi F Ghielmetti B Suarez-Merino, et al. 2006 Neurospheres enriched in cancer stem-like cells are highly effective in eliciting a dendritic cell-mediated immune response against malignant gliomas Cancer Res 66 21 10247 10252 17079441 10.1158/0008-5472.CAN-06-2048 1:CAS:528:DC%2BD28XhtFGjsrvO
14. Q Xu G Liu X Yuan M Xu H Wang J Ji, et al. 2009 Antigen-specific T-cell response from dendritic cell vaccination using cancer stem-like cell-associated antigens Stem Cells 27 8 1734 1740 19536809 10.1002/stem.102 1:CAS:528:DC%2BD1MXht1Wqu7fO
15. PM Ravdin GC Chamness 1995 The c-erbB-2 proto-oncogene as a prognostic and predictive marker in breast cancer: a paradigm for the development of other macromolecular markers-a review Gene 159 1 19 27 7607568 10.1016/0378-1119(94) 00866-Q 1:CAS:528:DyaK2MXmvFWru78%3D
16. AL Schechter DF Stern L Vaidyanathan SJ Decker JA Drebin MI Greene, et al. 1984 The neu oncogene: an erb-B-related gene encoding a 185, 000-Mr tumour antigen Nature 312 5994 513 516 6095109 10.1038/312513a0 1:CAS:528: DyaL2MXntlCmtA%3D%3D
17. DJ Slamon W Godolphin LA Jones JA Holt SG Wong DE Keith, et al. 1989 Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer Science 244 4905 707 712 2470152 10.1126/science.2470152 1:STN:280: DyaL1M3kt1Wntg%3D%3D
18. JA Freudenberg Q Wang M Katsumata J Drebin I Nagatomo MI Greene 2009 The role of HER2 in early breast cancer metastasis and the origins of resistance to HER2-targeted therapies Exp Mol Pathol 87 1 1 11 19450579 10.1016/j.yexmp.2009. 05.001 1:CAS:528:DC%2BD1MXotFOrtr8%3D
19. H Korkaya A Paulson F Iovino MS Wicha 2008 HER2 regulates the mammary stem/progenitor cell population driving tumorigenesis and invasion Oncogene 27 47 6120 6130 18591932 10.1038/onc.2008.207 1:CAS:528:DC%2BD1cXht1Cms7rJ
20. CN Baxevanis IF Voutsas AD Gritzapis SA Perez M Papamichail 2010 HER-2/neu as a target for cancer vaccines Immunotherapy 2 2 213 226 20635929 10.2217/imt.09.89 1:CAS:528:DC%2BC3cXivVCjsr0%3D
21. ML Disis SM Pupa JR Gralow R Dittadi S Menard MA Cheever 1997 High-titer HER-2/neu protein-specific antibody can be detected in patients with early-stage breast cancer J Clin Oncol 15 11 3363 3367 9363867 1:STN:280: DyaK1c%2FivVCqtQ%3D%3D
22. ML Disis E Calenoff G McLaughlin AE Murphy W Chen B Groner, et al. 1994 Existent T-cell and antibody immunity to HER-2/neu protein in patients with breast cancer Cancer Res 54 1 16 20 7505195 1:STN:280:DyaK2c%2FosVKrtQ%3D%3D
23. EA Mittendorf JP Holmes S Ponniah GE Peoples 2008 The E75 HER2/neu peptide vaccine Cancer Immunol Immunother 57 10 1511 1521 18536917 10.1007/s00262-008-0540-3 1:CAS:528:DC%2BD1cXovFyisbY%3D
24. ML Disis DR Wallace TA Gooley Y Dang M Slota H Lu, et al. 2009 Concurrent trastuzumab and HER2/neu-specific vaccination in patients with metastatic breast cancer J Clin Oncol 27 28 4685 4692 19720923 10.1200/JCO.2008.20.6789 1:CAS:528:DC%2BD1MXhtlGgtbnK
25. CT Guy MA Webster M Schaller TJ Parsons RD Cardiff WJ Muller 1992 Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease Proc Natl Acad Sci USA 89 22 10578 10582 1359541 10.1073/pnas.89.22.10578 1:CAS:528:DyaK3sXjs1ymsw%3D%3D
26. H Kagamu JE Touhalisky GE Plautz JC Krauss S Shu 1996 Isolation based on L-selectin expression of immune effector T cells derived from tumor-draining lymph nodes Cancer Res 56 19 4338 4342 8813119 1:CAS:528:DyaK28XmtVyltro%3D
27. LX Wang BG Chen GE Plautz 2002 Adoptive immunotherapy of advanced tumors with CD62 L-selectin (low) tumor-sensitized T lymphocytes following ex vivo hyperexpansion J Immunol 169 6 3314 3320 12218152 1:CAS:528:DC%2BD38XntFagsrY%3D
28. LX Wang WX Huang H Graor PA Cohen JA Kim S Shu, et al. 2004 Adoptive immunotherapy of cancer with polyclonal, 108-fold hyperexpanded, CD4+ and CD8+ T cells J Transl Med 2 1 41 15566571 10.1186/1479-5876-2-41
29. LX Wang S Shu ML Disis GE Plautz 2007 Adoptive transfer of tumor-primed, in vitro-activated, CD4+ T effector cells (TEs) combined with CD8+ TEs provides intratumoral TE proliferation and synergistic antitumor response Blood 109 11 4865 4876 17284532 10.1182/blood-2006-09-045245 1:CAS:528:DC%2BD2sXmt1Ogu74%3D
30. LX Wang S Shu GE Plautz 2005 Host lymphodepletion augments T cell adoptive immunotherapy through enhanced intratumoral proliferation of effector cells Cancer Res 65 20 9547 9554 16230420 10.1158/0008-5472.CAN-05-1175 1:CAS:528:DC%2BD2MXhtFWmu7rF
31. RT Reilly MB Gottlieb AM Ercolini JP Machiels CE Kane FI Okoye 2000 HER-2/neu is a tumor rejection target in tolerized HER-2/neu transgenic mice Cancer Res 60 13 3569 3576 10910070 1:CAS:528:DC%2BD3cXkvFChsb8%3D
32. AM Ercolini JP Machiels YC Chen JE Slansky M Giedlen RT Reilly, et al. 2003 Identification and characterization of the immunodominant rat HER-2/neu MHC class I epitope presented by spontaneous mammary tumors from HER-2/neu-transgenic mice J Immunol 170 8 4273 4280 12682262 1:CAS:528:DC%2BD3sXislers7c%3D
33. AM Ercolini BH Ladle EA Manning LW Pfannenstiel TD Armstrong JP Machiels, et al. 2005 Recruitment of latent pools of high-avidity CD8(+) T cells to the antitumor immune response J Exp Med 201 10 1591 1602 15883172 10.1084/jem.20042167 1:CAS:528:DC%2BD2MXktlygu7c%3D
34. GE Plautz S Mukai PA Cohen S Shu 2000 Cross-presentation of tumor antigens to effector T cells is sufficient to mediate effective immunotherapy of established intracranial tumors J Immunol 165 7 3656 3662 11034369 1:CAS:528:DC%2BD3cXntVyju7Y%3D
35. MJ Meyer JM Fleming MA Ali MW Pesesky E Ginsburg BK Vonderhaar 2009 Dynamic regulation of CD24 and the invasive, CD44posCD24neg phenotype in breast cancer cell lines Breast Cancer Res 11 6 R82 19906290 10.1186/bcr2449
36. LX Wang J Kjaergaard PA Cohen S Shu GE Plautz 2004 Memory T cells originate from adoptively transferred effectors and reconstituting host cells after sequential lymphodepletion and adoptive immunotherapy J Immunol 172 6 3462 3468 15004146 1:CAS:528:DC%2BD2cXhvVKjt7s%3D
37. R Singh ME Dominiecki EM Jaffee Y Paterson 2005 Fusion to Listeriolysin O and delivery by Listeria monocytogenes enhances the immunogenicity of HER-2/neu and reveals subdominant epitopes in the FVB/N mouse J Immunol 175 6 3663 3673 16148111 1:CAS:528:DC%2BD2MXpslClsr4%3D
38. R Singh Y Paterson 2006 Vaccination strategy determines the emergence and dominance of CD8+ T-cell epitopes in a FVB/N rat HER-2/neu mouse model of breast cancer Cancer Res 66 15 7748 7757 16885378 10.1158/0008-5472.CAN-05-4469 1:CAS:528:DC%2BD28XnsFyqsrg%3D
39. JN Uram CM Black E Flynn L Huang TD Armstrong EM Jaffee 2011 Nondominant CD8 T cells are active players in the vaccine-induced antitumor immune response J Immunol 186 7 3847 3857 21346233 10.4049/jimmunol.1000361 1:CAS:528: DC%2BC3MXjvVKmt74%3D
40. Wood LD, Parsons DW, Jones S, Lin J, Sjoblom T, Leary RJ et al (2007) The genomic landscapes of human breast and colorectal cancers. Science 318(5853): 1108-1113. doi: 10.1126/science.1145720
41. PJ Stephens DJ McBride ML Lin I Varela ED Pleasance JT Simpson, et al. 2009 Complex landscapes of somatic rearrangement in human breast cancer genomes Nature 462 7276 1005 1010 20033038 10.1038/nature08645 1:CAS:528: DC%2BD1MXhs1SktbrN
42. D Atanackovic J Arfsten Y Cao S Gnjatic F Schnieders K Bartels, et al. 2007 Cancer-testis antigens are commonly expressed in multiple myeloma and induce systemic immunity following allogeneic stem cell transplantation Blood 109 3 1103 1112 17023585 10.1182/blood-2006-04-014480 1:CAS:528: DC%2BD2sXjtFert7g%3D
43. H Bernhard J Neudorfer K Gebhard H Conrad C Hermann J Nahrig, et al. 2008 Adoptive transfer of autologous, HER2-specific, cytotoxic T lymphocytes for the treatment of HER2-overexpressing breast cancer Cancer Immunol Immunother 57 2 271 280 17646988 10.1007/s00262-007-0355-7
44. P Nanni L Landuzzi G Nicoletti C De Giovanni I Rossi S Croci, et al. 2004 Immunoprevention of mammary carcinoma in HER-2/neu transgenic mice is IFN-gamma and B cell dependent J Immunol 173 4 2288 2296 15294941 1:CAS:528: DC%2BD2cXmt1Olsr8%3D